Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

Filiaciones

Jonas B.A.:

Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, United States

DiNardo C.:

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Fracchiolla N.:

Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

Ishizawa K.:

Department of Internal Medicine III, Yamagata University Faculty of Medicine, Yamagata, Japan

Jin J.:

Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Zhejiang, Hangzhou, China

Konopleva M.:

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Ofran Y.:

Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

Montesinos P.:

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

Kovacsovics T.:

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States

Kantarjian H.:

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Duan Y.:

AbbVie, Inc, North Chicago, IL, United States

Potluri J.:

AbbVie, Inc, North Chicago, IL, United States

Werner M.:

AbbVie, Inc, North Chicago, IL, United States

Pratz K.W.:

Department of Medicine, Hematology-Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, PA, United States